1 |
BROWN L J, OLIVER R C, LÖE H. Periodontal diseases in the US in 1981: prevalence, severity, extent, and role in tooth mortality[J]. J Periodontol, 1989, 60(7): 363-370.
|
2 |
KASSEBAUM N J, BERNABÉ E, DAHIYA M, et al. Global burden of severe periodontitis in 1990‒2010: a systematic review and meta-regression[J]. J Dent Res, 2014, 93(11): 1045-1053.
|
3 |
SANZ M, MARCO DEL CASTILLO A, JEPSEN S, et al. Periodontitis and cardiovascular diseases: consensus report[J]. J Clin Periodontol, 2020, 47(3): 268-288.
|
4 |
HAJISHENGALLIS G, CHAVAKIS T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities[J]. Nat Rev Immunol, 2021, 21(7): 426-440.
|
5 |
BOURGEOIS D, INQUIMBERT C, OTTOLENGHI L, et al. Periodontal pathogens as risk factors of cardiovascular diseases, diabetes, rheumatoid arthritis, cancer, and chronic obstructive pulmonary disease: is there cause for consideration? [J]. Microorganisms, 2019, 7(10): 424.
|
6 |
HILL J A, OLSON E N. Cardiac plasticity[J]. N Engl J Med, 2008, 358(13): 1370-1380.
|
7 |
SHIMIZU I, MINAMINO T. Physiological and pathological cardiac hypertrophy[J]. J Mol Cell Cardiol, 2016, 97: 245-262.
|
8 |
NAKAMURA M, SADOSHIMA J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol, 2018, 15(7): 387-407.
|
9 |
BAI L, CHEN B Y, LIU Y, et al. A mouse periodontitis model with humanized oral bacterial community[J]. Front Cell Infect Microbiol, 2022, 12: 842845.
|
10 |
WEI X, WU B, ZHAO J, et al. Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of S100A8/A9[J]. Circulation, 2015, 131(17): 1506-1517;discussion1517.
|
11 |
ZAURA E, KEIJSER B J F, HUSE S M, et al. Defining the healthy “core microbiome” of oral microbial communities[J]. BMC Microbiol, 2009, 9: 259.
|
12 |
SEGATA N, IZARD J, WALDRON L, et al. Metagenomic biomarker discovery and explanation[J]. Genome Biol, 2011, 12(6): R60.
|
13 |
KOREN O, SPOR A, FELIN J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis[J]. Proc Natl Acad Sci U S A, 2011, 108(Suppl 1): 4592-4598.
|
14 |
KINANE D F, STATHOPOULOU P G, PAPAPANOU P N. Periodontal diseases[J]. Nat Rev Dis Primers, 2017, 3: 17038.
|
15 |
ARMINGOHAR Z, JØRGENSEN J J, KRISTOFFERSEN A K, et al. Bacteria and bacterial DNA in atherosclerotic plaque and aneurysmal wall biopsies from patients with and without periodontitis[J]. J Oral Microbiol, 2014, 6. DOI: 10.3402/jom.v6.23408.eCollection 2014.
|
16 |
MAHENDRA J, MAHENDRA L, FELIX J, et al. Prevelance of periodontopathogenic bacteria in subgingival biofilm and atherosclerotic plaques of patients undergoing coronary revascularization surgery[J]. J Indian Soc Periodontol, 2013, 17(6): 719-724.
|
17 |
SHI B C, LUX R, KLOKKEVOLD P, et al. The subgingival microbiome associated with periodontitis in type 2 diabetes mellitus[J]. ISME J, 2020, 14(2): 519-530.
|
18 |
LIU X H, TIAN K, MA X R, et al. Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: a case-control study[J]. Saudi J Biol Sci, 2020, 27(7): 1835-1842.
|
19 |
KNÖLL R, IACCARINO G, TARONE G, et al. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC[J]. Eur J Heart Fail, 2011, 13(8): 811-819.
|
20 |
MCLELLAN A J A, ELLIMS A H, PRABHU S, et al. Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy[J]. J Cardiovasc Electrophysiol, 2016, 27(5): 571-580.
|
21 |
ALMAAS V M, HAUGAA K H, STRØM E H, et al. Increased amount of interstitial fibrosis predicts ventricular arrhythmias, and is associated with reduced myocardial septal function in patients with obstructive hypertrophic cardiomyopathy[J]. Europace, 2013, 15(9): 1319-1327.
|
22 |
MANN D L. Innate immunity and the failing heart: the cytokine hypothesis revisited[J]. Circ Res, 2015, 116(7): 1254-1268.
|
23 |
TRACHTENBERG B H, HARE J M. Inflammatory cardiomyopathic syndromes[J]. Circ Res, 2017, 121(7): 803-818.
|
24 |
HEUSCH G, LIBBY P, GERSH B, et al. Cardiovascular remodelling in coronary artery disease and heart failure[J]. Lancet, 2014, 383(9932): 1933-1943.
|
25 |
WEI Y P, SHI M, ZHEN M, et al. Comparison of subgingival and buccal mucosa microbiome in chronic and aggressive periodontitis: a pilot study[J]. Front Cell Infect Microbiol, 2019, 9: 53.
|
26 |
JI S, KIM Y, MIN B M, et al. Innate immune responses of gingival epithelial cells to nonperiodontopathic and periodontopathic bacteria[J]. J Periodontal Res, 2007, 42(6): 503-510.
|
27 |
PINHO-GOMES A C, NASIR A, MOSCA R, et al. Intraoperative diagnosis of mitral valve endocarditis secondary to Paenibacillus provencensis[J]. Ann R Coll Surg Engl, 2017, 99(2): e54-e55.
|
28 |
ZIGANSHINA E E, SHARIFULLINA D M, LOZHKIN A P, et al. Bacterial communities associated with atherosclerotic plaques from Russian individuals with atherosclerosis[J]. PLoS One, 2016, 11(10): e0164836.
|
29 |
SCHÄFFLER H, HERLEMANN D P R, ALBERTS C, et al. Mucosa-attached bacterial community in Crohn′s disease coheres with the clinical disease activity index[J]. Environ Microbiol Rep, 2016, 8(5): 614-621.
|
30 |
WANG Z N, HAZEN J, JIA X, et al. The nutritional supplement L-alpha glycerylphosphorylcholine promotes atherosclerosis[J]. Int J Mol Sci, 2021, 22(24): 13477.
|
31 |
TOYA T, CORBAN M T, MARRIETTA E, et al. Coronary artery disease is associated with an altered gut microbiome composition[J]. PLoS One, 2020, 15(1): e0227147.
|
32 |
LI Z H, WU Z Y, YAN J Y, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis[J]. Lab Invest, 2019, 99(3): 346-357.
|
33 |
ZHAO M M, WEI H R, LI C Z, et al. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy[J]. Nat Commun, 2022, 13(1): 1757.
|
34 |
HEINEKE J, MOLKENTIN J D. Regulation of cardiac hypertrophy by intracellular signalling pathways[J]. Nat Rev Mol Cell Biol, 2006, 7(8): 589-600.
|
35 |
BILLET S, BARDIN S, VERP S, et al. Gain-of-function mutant of angiotensin Ⅱ receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice[J]. J Clin Invest, 2007, 117(7): 1914-1925.
|
36 |
BOUTHIER J D, DE LUCA N, SAFAR M E, et al. Cardiac hypertrophy and arterial distensibility in essential hypertension[J]. Am Heart J, 1985, 109(6): 1345-1352.
|
37 |
SRIVASTAVA P M, CALAFIORE P, MACISAAC R J, et al. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with type 2 diabetes[J]. Clin Sci (Lond), 2008, 114(4): 313-320.
|
38 |
HU Q X, ZHANG H L, GUTIÉRREZ CORTÉS N, et al. Increased Drp1 acetylation by lipid overload induces cardiomyocyte death and heart dysfunction[J]. Circ Res, 2020, 126(4): 456-470.
|
39 |
RUBIN S A, FISHBEIN M C, SWAN H J. Compensatory hypertrophy in the heart after myocardial infarction in the rat[J]. J Am Coll Cardiol, 1983, 1(6): 1435-1441.
|
40 |
PFEFFER M A, BRAUNWALD E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications[J]. Circulation, 1990, 81(4): 1161-1172.
|
41 |
EVERETT R J, TASTET L, CLAVEL M A, et al. Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study[J]. Circ Cardiovasc Imaging, 2018, 11(6): e007451.
|